A PHASE 3 RANDOMIZED, DOUBLE-BLINDED, PLACEBO-CONTROLLED MULTICENTER TRIAL WITH OPEN-LABEL EXTENSION TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF EFGARTIGIMOD PH20 SUBCUTANEOUS ADMINISTERED BY PREFILLED SYRINGE IN ADULT PATIENTS WITH PRIMARY SJÖGREN¿S DISEASE

Registry ID

ARGX-113-2306

Source registry

HEALTH_CANADA

Status

Ongoing

Phase

PHASE3

Study type

INTERVENTIONAL

Sponsor

ARGENX BV

Start date

2025-03-11

Last update

2024-11-20

Conditions

• PRIMARY SJOGREN'S SYNDROME (PSJS)

Related clinical trials

• A PHASE 2B, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY, SAFETY, AND TOLERABILITY OF IMVT- 1402 IN ADULT PARTICIPANTS WITH PRIMARY SJOGREN’S DISEASE WITH MODERATE TO SEVERE SYSTEMIC DISEASE ACTIVITY

View on source registry